Elicio Therapeutics, Inc. Overview
Pro stress-test →Elicio Therapeutics is a clinical-stage biotechnology company advancing novel immunotherapies for the treatment of high-prevalence cancers, including mKRAS-positive pancreatic and colorectal cancers. The company focuses on developing effective, off-the-shelf immunotherapies using its proprietary Amphiphile (AMP) technology, which aims to enhance the education, activation, and amplification of cancer-specific T cells to promote durable cancer immunosurveillance.
Strategic Profile
Pro stress-test →The lead program, ELI-002 7P, is a lymph node-targeted cancer immunotherapy currently being evaluated in a Phase 2 study for mKRAS pancreatic ductal adenocarcinoma (PDAC). However, the Phase 2 AMPLIFY-7P study did not meet the pre-specified primary endpoint of disease-free survival (DFS) in the intent-to-treat population (June 15, 2026). The company's cash runway is expected to extend into Q4 2026, beyond the anticipated DFS readout.
Competitive Landscape
Pro stress-test →Elicio competes in the personalized and off-the-shelf cancer immunotherapy space. Key competitors include established immunotherapy platforms from larger biotech and pharma companies developing KRAS-targeted therapies and checkpoint inhibitors. The company's lymph node-targeting approach via its AMP technology differentiates it, but the Phase 2 failure puts it at a competitive disadvantage versus clinical-stage rivals advancing similar mechanisms in pancreatic cancer.
Industry Context
Elicio Therapeutics, Inc. operates in Cancer immunotherapy development.
Key facts
Founded: 2011 · Headquarters: Boston, US · Employees: Unknown · Revenue: N/A · Market cap: $283M